Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News BELLUS Health Inc. T.BLU

Alternate Symbol(s):  BLU

Healthcare Biotechnology
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:BLU)

Fundamentals Snapshot (TSX:BLU)

Current News (TSX:BLU)

BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition

Business Wire May 16, 2023

BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

Business Wire May 12, 2023

BELLUS Health Announces Meeting Updates

Business Wire April 26, 2023

Moore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law Firm

PR Newswire April 21, 2023

GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

Business Wire April 18, 2023

Top U.S. pharma multibillion-dollar offer sends clinical-stage company stock surging

Jon Brown April 18, 2023

BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation

Business Wire April 5, 2023

BELLUS Health Reports Year 2022 Financial Results and Business Highlights

Business Wire March 21, 2023

BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

Business Wire March 1, 2023
View More News ››

Opinion & Analysis (TSX:BLU)

Coverage resumed on developer of 'drug candidate with blockbuster potential'

Streetwise Reports January 24, 2018
View More Opinion ››

Bullboard Posts (TSX:BLU)

The wonderful Bellus story: not ours.

2 very different stories. those of Bellus' chronic cough medicine and Spectral Medical's septic shock treatment. BLU-5937 phase...
Stocktree - April 20, 2023

A FEW QUESTIONS ...?

If GSK  IS BUYING BLU at  14.45 $ US ; why are people selling for lower? Why is this still trading anyways ? MINEDRILLER you...
blueblack - April 18, 2023

RE:RE:GSK offer at $14.75 cash USD

That's really a decision only you can make. If it was my choice , I would tend to keep the shares and let it all unfold.It's a...
Possibleidiot01 - April 18, 2023

RE:GSK offer at $14.75 cash USD

What's better to do ... sell all our shares or wait and see?
Sw33tP3t3 - April 18, 2023

RE:GSK offer at $14.75 cash USD

Reposting because the offer news release  has yet to be posted on SH
Possibleidiot01 - April 18, 2023

GSK offer at $14.75 cash USD

1 minute readApril 18, 20232:40 AM EDTLast Updated 5 min ago GSK to buy Canada's Bellus Health for $2 bln Reuters ...
Possibleidiot01 - April 18, 2023
View more Bullboard ››

Star Navigation Systems Group

Star Navigation Systems Group

Star Navigation Systems Group Ltd is focused on providing Aerospace Solutions. It is centred on devoting all its activity to ...
View More »